Abivax Publishes Results of Obefazimod (ABX464) in P-IIb Trial for the Treatment of Ulcerative Colitis in the Lancet Gastroenterology & Hepatology
- The P-IIb study evaluates obefazimod (25/50/100mg, OD) vs PBO for 8wks. in patients (n=254) with moderate/severe active UC. Patients (n=222) who completed the P-IIb induction study were enrolled in a maintenance study evaluating the safety & efficacy of obefazimod (50mg, OD) for 2yrs.
- The results of the study demonstrated that the study met its 1EP & 2EPs incl. endoscopic improvement, clinical remission, clinical response & a reduction of fecal calprotectin indicating a significant difference vs PBO
- Abivax & IQVIA will jointly initiate the P-III study evaluating obefazimod (25/50mg) by the end of Sep’22 across the US, Europe, Japan & other geographical locations with 430 out of 600 study sites qualified for the P-III trial
Ref: accesswire | Image: Abivax
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].